Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus letrozole and capecitabine in advanced breast cancer
NCT05469750Phase 2Unknown
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Fujian Medical University Union Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05469750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469750.